Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.9 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -26.31 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.47 | |||||
Beneish M-Score | -2.03 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7 | |||||
3-Year EBITDA Growth Rate | 50.3 | |||||
3-Year EPS without NRI Growth Rate | 44.7 | |||||
3-Year Book Growth Rate | 9.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -39.03 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.9 | |||||
9-Day RSI | 36.71 | |||||
14-Day RSI | 37.03 | |||||
6-1 Month Momentum % | -24.54 | |||||
12-1 Month Momentum % | -24.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.51 | |||||
Quick Ratio | 9.51 | |||||
Cash Ratio | 9.25 | |||||
Days Sales Outstanding | 45.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | -36.22 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4.63 | |||||
Net Margin % | 6.28 | |||||
FCF Margin % | -15.93 | |||||
ROE % | 3.5 | |||||
ROA % | 2.42 | |||||
ROIC % | -6.55 | |||||
3-Year ROIIC % | 345.81 | |||||
ROC (Joel Greenblatt) % | -14.82 | |||||
ROCE % | -2.1 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 28.55 | |||||
PE Ratio without NRI | 28.55 | |||||
PS Ratio | 2.29 | |||||
PB Ratio | 1.02 | |||||
Price-to-Tangible-Book | 1.05 | |||||
EV-to-EBIT | -2.76 | |||||
EV-to-EBITDA | -10.31 | |||||
EV-to-Forward-EBITDA | -0.17 | |||||
EV-to-Revenue | 0.13 | |||||
EV-to-Forward-Revenue | 0.24 | |||||
EV-to-FCF | -0.83 | |||||
Price-to-Projected-FCF | 3.52 | |||||
Price-to-Graham-Number | 1.17 | |||||
Price-to-Net-Current-Asset-Value | 1.26 | |||||
Price-to-Net-Cash | 1.31 | |||||
Earnings Yield (Greenblatt) % | -36.23 | |||||
FCF Yield % | -6.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Voyager Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 132.342 | ||
EPS (TTM) (€) | 0.187 | ||
Beta | 0.79 | ||
Volatility % | 74.77 | ||
14-Day RSI | 37.03 | ||
14-Day ATR (€) | 0.155133 | ||
20-Day SMA (€) | 5.77225 | ||
12-1 Month Momentum % | -24.54 | ||
52-Week Range (€) | 5.395 - 10.1 | ||
Shares Outstanding (Mil) | 54.53 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Voyager Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Voyager Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Voyager Therapeutics Inc Frequently Asked Questions
What is Voyager Therapeutics Inc(FRA:VT6)'s stock price today?
When is next earnings date of Voyager Therapeutics Inc(FRA:VT6)?
Does Voyager Therapeutics Inc(FRA:VT6) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |